Literature DB >> 6310083

Effects of glial uptake and desensitization on the activity of gamma-aminobutyric acid (GABA) and its analogs at the cat dorsal root ganglion.

J P Gallagher, J Nakamura, P Shinnick-Gallagher.   

Abstract

Responses to gamma-aminobutyric acid (GABA) and 13 structurally related analogs were recorded under voltage clamp conditions from isolated cat dorsal root ganglia (DRG). All of the analogs were applied by superfusion at a concentration of 1 mM. Of the 13 structurally related compounds, only muscimol was more effective than GABA in its ability to produce an inward current at the DRG membrane. Complete (1 microM-10 mM) concentration-response relationships were obtained for muscimol, GABA and 3-aminopropane sulfonic acid. Muscimol was most potent at all concentrations, however, the relative order of potency for GABA and 3-aminopropane sulfonic acid was concentration-dependent. In addition to producing differences in their peak currents, the various agonists demonstrated different time courses in their respective rates of decay. When the glial uptake system for GABA in cat DRG was inhibited by substituting lithium for sodium or by the addition of 1 mM nipecotic acid to the normal Krebs' solution, the membrane responses to GABA, SL-75102 and isoguvacine were facilitated, whereas the responses induced by the other analogs remained unchanged. Although the process of uptake altered significantly the decay phase of GABA responses when GABA was applied by superfusion or by iontophoresis, nipecotic acid inhibition of uptake did not appear to affect GABA-induced desensitization that was apparent when GABA was applied either by superfusion or with long iontophoretic pulses. GABA and all of the analogs in this study demonstrated cross-desensitization, each being able to depress the action of the other. Our results suggest that all of the active GABA analogs appear to be acting at a similar GABA receptor on cat DRG and this GABA receptor is coupled to a chloride channel.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6310083

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Frequency-dependent depression of inhibition in guinea-pig neocortex in vitro by GABAB receptor feed-back on GABA release.

Authors:  R A Deisz; D A Prince
Journal:  J Physiol       Date:  1989-05       Impact factor: 5.182

2.  An arylaminopyridazine derivative of gamma-aminobutyric acid (GABA) is a selective and competitive antagonist at the GABAA receptor site.

Authors:  J P Chambon; P Feltz; M Heaulme; S Restle; R Schlichter; K Biziere; C G Wermuth
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

3.  Entanglement between thermoregulation and nociception in the rat: the case of morphine.

Authors:  Nabil El Bitar; Bernard Pollin; Elias Karroum; Ivanne Pincedé; Daniel Le Bars
Journal:  J Neurophysiol       Date:  2016-09-07       Impact factor: 2.714

4.  Silencing the α2 subunit of γ-aminobutyric acid type A receptors in rat dorsal root ganglia reveals its major role in antinociception posttraumatic nerve injury.

Authors:  Aleksandar L Obradovic; Joseph Scarpa; Hari P Osuru; Janelle L Weaver; Ji-Yong Park; Sriyani Pathirathna; Alexander Peterkin; Yunhee Lim; Miljenko M Jagodic; Slobodan M Todorovic; Vesna Jevtovic-Todorovic
Journal:  Anesthesiology       Date:  2015-09       Impact factor: 7.892

5.  Recombinant GABAA receptor desensitization: the role of the gamma 2 subunit and its physiological significance.

Authors:  C Dominguez-Perrot; P Feltz; M O Poulter
Journal:  J Physiol       Date:  1996-11-15       Impact factor: 5.182

6.  Diazepam action on gamma-aminobutyric acid-activated chloride currents in internally perfused frog sensory neurons.

Authors:  K Hattori; Y Oomura; N Akaike
Journal:  Cell Mol Neurobiol       Date:  1986-09       Impact factor: 5.046

Review 7.  Chloride - The Underrated Ion in Nociceptors.

Authors:  Bettina U Wilke; Kai K Kummer; Michael G Leitner; Michaela Kress
Journal:  Front Neurosci       Date:  2020-04-08       Impact factor: 4.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.